1-7 of 7
Marcus Schittenhelm
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Clonal evolution in relapsed NPM1 -mutated acute myeloid leukemia

Jan Krönke, Lars Bullinger, Veronica Teleanu, Florian Tschürtz, Verena I. Gaidzik, Michael W. M. Kühn, Frank G. Rücker, Karlheinz Holzmann, Peter Paschka, Silke Kapp-Schwörer, Daniela Späth, Thomas Kindler, Marcus Schittenhelm, Jürgen Krauter, Arnold Ganser, Gudrun Göhring, Brigitte Schlegelberger, Richard F. Schlenk, Hartmut Döhner, Konstanze Döhner
Journal: Blood
Blood (2013) 122 (1): 100–108.
https://doi.org/10.1182/blood-2013-01-479188
Published: 2013
Includes: Supplemental data
Journal Articles

The Heatshockprotein-90 Inhibitor IPI-504 Potently Overcomes Tyrosinekinase Inhibitor-Induced Activation of Cell Protection Mechanisms and Degrades HSP-Client Proteins KIT and FLT3 In Acute Leukemia Models

Marcus Schittenhelm, Dr., MD, Tanja Grandl, Emmanuel Normant, PharmD, PhD, Helmut R. Salih, MD, Kerstin M Kampa-Schittenhelm, Dr., MD
Journal: Blood
Blood (2010) 116 (21): 3982.
https://doi.org/10.1182/blood.V116.21.3982.3982
Published: 2010
Journal Articles

ASPP2 Expression In Acute Leukemia Modulates Response to Therapy

Kerstin M Kampa-Schittenhelm, Dr., MD, Charles D Lopez, Md, PhD, Marcus Schittenhelm, Dr., MD
Journal: Blood
Blood (2010) 116 (21): 3143.
https://doi.org/10.1182/blood.V116.21.3143.3143
Published: 2010
Journal Articles

AC220, a Potent Second Generation Class I/III Tyrosine Kinase Inhibitor, Displays a Distinct Inhibition Profile on Mutant-FLT3 as Well as -KIT Isoforms

Kerstin M Kampa-Schittenhelm, MD, Mohit Trikha, Richard F. Schlenk, MD, Hartmut Doehner, MD, Konstanze Doehner, MD, Michael C. Heinrich, MD, Marcus Schittenhelm, MD
Journal: Blood
Blood (2010) 116 (21): 291.
https://doi.org/10.1182/blood.V116.21.291.291
Published: 2010
Journal Articles

Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD–positive leukemic cells

Kevin W. H. Yee, Marcus Schittenhelm, Anne-Marie O'Farrell, Ajia R. Town, Laura McGreevey, Troy Bainbridge, Julie M. Cherrington, Michael C. Heinrich
Journal: Blood
Blood (2004) 104 (13): 4202–4209.
https://doi.org/10.1182/blood-2003-10-3381
Published: 2004
Journal Articles

Mutations of Oncogenes Involved in Signal Transduction Pathways Are Common in AML.

Michael C. Heinrich, M.D., Andrea Haley, Patina Harell, Ajia Town, Troy Bainbridge, Marcus Schittenhelm, M.D., Laura McGreevey, Rita Braziel, M.D.
Journal: Blood
Blood (2004) 104 (11): 2575.
https://doi.org/10.1182/blood.V104.11.2575.2575
Published: 2004
Journal Articles

BMS-354825 Potently Inhibits the Kinase Activity of KIT Activation Loop Mutations Associated with Systemic Mastocytosis and Induces Apoptosis of Mastocytosis Cell Lines.

Marcus Schittenhelm, M.D., Sharon Shiraga, Francis Y. Lee, Ph.D., Michael C. Heinrich, M.D.
Journal: Blood
Blood (2004) 104 (11): 2424.
https://doi.org/10.1182/blood.V104.11.2424.2424
Published: 2004